The Canakinumab Anti-inflammatory Thrombosis Outcome Study trial also provides strong support for the hypothesis that the NLRP3 inflammasome pathway contributes to the pathogenesis of the atherosclerotic disease, demonstrating diverse clinical benefits of inhibiting IL-1β for cardiovascular events32. The gene discussed is NLRP3; the disease is Venous thrombosis.